Novartis Ends Study Assessing Antibody in Kidney Transplant Patients

Novartis has stopped a phase 2 study evaluating CFZ533 (iscalimab) in kidney transplant patients but said it will continue to assess the monoclonal antibody in liver transplant patients.

An interim analysis showed the antibody to be less effective than the immunosuppressive drug tacrolimus in preventing organ rejection for patients undergoing a kidney transplant, the company said. Iscalimab and tacrolimus were tested in combination with other immunosuppressants, including induction therapy, mycophenolate and corticosteroids.

Novartis said studies evaluating CFZ533 will continue for liver transplant patients as well as for other ailments, including the chronic skin condition hidradenitis suppurativa and Sjögren’s syndrome, an immune system disorder resulting in dry eyes and mouth.